PMID- 30445271
OWN - NLM
STAT- MEDLINE
DCOM- 20190107
LR  - 20190610
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 72
DP  - 2019 Jan
TI  - EGFR-directed monoclonal antibodies in combination with chemotherapy for 
      treatment of non-small-cell lung cancer: an updated review of clinical trials and 
      new perspectives in biomarkers analysis.
PG  - 15-27
LID - S0305-7372(18)30137-3 [pii]
LID - 10.1016/j.ctrv.2018.08.002 [doi]
AB  - Lung cancer still represents one of the most common and fatal neoplasm, 
      accounting for nearly 30% of all cancer-related deaths. Targeted therapies based 
      on molecular tumor features and programmed death-1 (PD-1)/programmed death 
      ligand-1 (PDL-1) blockade immunotherapy have offered new therapeutic options for 
      patients with advanced non-small-cell lung cancer (NSCLC). Activation of the 
      epidermal growth factor receptor (EGFR)-pathway promotes tumor growth and 
      progression, including angiogenesis, invasion, metastasis and inhibition of 
      apoptosis, providing a strong rationale for targeting this pathway. EGFR 
      expression is detected in up to 85% of NSCLC and has been demonstrated to be 
      associated with poor prognosis. Two approaches for blocking EGFR signaling are 
      available: prevention of ligand binding to the extracellular domain with 
      monoclonal antibodies (mAbs) and inhibition of the intracellular tyrosine kinase 
      activity with small molecules. There is a strong rationale to consider the 
      tumor's level of EGFR expression as one of the most significant predictive 
      biomarkers in this setting. In this paper we provide an update focusing on the 
      current status of EGFR-directed mAbs use for the treatment of patients with 
      advanced NSCLC, through a review of all clinical trials involving anti-EGFR mAbs 
      in combination with chemotherapy (CT) for advanced disease and with 
      chemo-radiotherapy for stage III disease. Here we also discuss the current status 
      of predictive biomarkers for anti-EGFR mAbs when added to first-line CT in 
      patients with advanced NSCLC. Finally, we focused on the relevance of EGFR 
      fluorescence in situ hybridization (FISH)+ and immunohistochemistry 
      (IHC)-Score >/= 200 as predictive biomarkers for the selection of patients who 
      would be most likely to derive a clinical benefit from treatment with CT in 
      combination with anti-EGFR mAbs, with particular reference also to histology.
CI  - Copyright (c) 2018. Published by Elsevier Ltd.
FAU - Agustoni, Francesco
AU  - Agustoni F
AD  - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 
      Aurora, CO, United States.
FAU - Suda, Kenichi
AU  - Suda K
AD  - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 
      Aurora, CO, United States; Division of Thoracic Surgery, Department of Surgery, 
      Kindai University, Faculty of Medicine, Osaka-Sayama, Japan.
FAU - Yu, Hui
AU  - Yu H
AD  - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 
      Aurora, CO, United States.
FAU - Ren, Shengxiang
AU  - Ren S
AD  - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 
      Aurora, CO, United States; Department of Medical Oncology, Shanghai Pulmonary 
      Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, 
      Shanghai, China.
FAU - Rivard, Christopher J
AU  - Rivard CJ
AD  - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 
      Aurora, CO, United States.
FAU - Ellison, Kim
AU  - Ellison K
AD  - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 
      Aurora, CO, United States.
FAU - Caldwell, Charles Jr
AU  - Caldwell C Jr
AD  - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 
      Aurora, CO, United States.
FAU - Rozeboom, Leslie
AU  - Rozeboom L
AD  - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 
      Aurora, CO, United States.
FAU - Brovsky, Kristine
AU  - Brovsky K
AD  - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 
      Aurora, CO, United States.
FAU - Hirsch, Fred R
AU  - Hirsch FR
AD  - Division of Medical Oncology, University of Colorado Anschutz Medical Campus, 
      Aurora, CO, United States. Electronic address: fred.hirsch@ucdenver.edu.
LA  - eng
GR  - U10 CA180888/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Review
DEP - 20180804
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Antineoplastic Agents/*therapeutic use
MH  - Antineoplastic Agents, Immunological/*therapeutic use
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy
MH  - ErbB Receptors/antagonists & inhibitors
MH  - Humans
MH  - Immunotherapy/methods
MH  - Lung Neoplasms/*drug therapy
OTO - NOTNLM
OT  - Biomarker
OT  - Chemotherapy
OT  - EGFR
OT  - FISH
OT  - IHC
OT  - Monoclonal antibodies
OT  - NSCLC
EDAT- 2018/11/18 06:00
MHDA- 2019/01/08 06:00
CRDT- 2018/11/17 06:00
PHST- 2017/11/22 00:00 [received]
PHST- 2018/07/30 00:00 [revised]
PHST- 2018/08/03 00:00 [accepted]
PHST- 2018/11/18 06:00 [pubmed]
PHST- 2019/01/08 06:00 [medline]
PHST- 2018/11/17 06:00 [entrez]
AID - S0305-7372(18)30137-3 [pii]
AID - 10.1016/j.ctrv.2018.08.002 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2019 Jan;72:15-27. doi: 10.1016/j.ctrv.2018.08.002. Epub 2018 
      Aug 4.